|
Basic Characteristics of Mutations
|
|
Mutation Site
|
C592G |
|
Mutation Site Sentence
|
In addition, C592G (known to have IC50=2.9) also increased 3 times. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
UL97 |
|
Standardized Encoding Gene
|
UL97
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cytomegalovirus infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
GCV |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
22300656
|
|
Title
|
Detection of ganciclovir resistance mutations by pyrosequencing in HCMV-infected pediatric patients
|
|
Author
|
Benzi F,Vanni I,Cassina G,Ugolotti E,Di Marco E,Cirillo C,Cristina E,Morreale G,Melioli G,Malnati M,Biassoni R
|
|
Journal
|
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
|
|
Journal Info
|
2012 May;54(1):48-55
|
|
Abstract
|
BACKGROUND: Human cytomegalovirus (HCMV) is an opportunistic pathogen especially for immuno-suppressed subjects that might develop pharmacological resistance in patients undergoing prolonged antiviral treatment. Ganciclovir (GCV) is the drug used as first choice therapy in affected children and a GCV-resistant phenotype is mainly linked to mutations of the viral protein kinase UL97. OBJECTIVES: Here a new quantitative pyrosequence (PSQ) method is presented that allows detection and quantification of the viral species carrying the more frequent UL97 mutations responsible for GCV resistance in clinical samples (>80% of known cases). STUDY DESIGN: The system has been validated using two independent approaches (cloning and sequencing of UL-97 gene fragments and real-time PCR) and clinical samples derived from 3 pediatric patients. RESULTS: The UL97 pyrosequencing analysis has indicated a significant increase of mutant viruses carrying the H520Q and C592G mutations. In particular, the H520Q viral mutation, known to increase GCV resistance (IC50=10) increased around 5 times during hospitalization. In addition, C592G (known to have IC50=2.9) also increased 3 times. CONCLUSIONS: PSQ is a quick, cheap, high throughput and sensitive analysis method to detect GCV-associated resistance mutation useful to follow antiviral therapy in perinatal CMV-infection as well as in immune-suppressed patients.
|
|
Sequence Data
|
HM208322;HM208323;HM208324;HM208325;HM208326;HM208327;HM208328;HM208329;HM208330;HM352646;HM352647;HM352648;HM352649
|